IMUX

Immunic Inc

$8.80

chg

-0.46 (-4.97%)

quotes and stock data may be delayed 15 minutes

52 wk low

8.64

52 wk hi

28.21

Cash

$127.5M

Burn Rate (Qtr)

$14.0M

Mkt Cap

$231.0m

Avg Volume

330,279

*cash/burn updated:

Q4 '20

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

IMU-838

Multiple sclerosis, Autoimmune disease

Phase 3

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IMU-838

Inflammatory bowel disease, Bowel disorder, Ulcerative colitis

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IMU-838 (vidofludimus calcium) | CALVID-1

COVID-19, Infectious disease

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IMU-838

Inflammatory bowel disease, Ulcerative colitis, Bowel disorder

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IMU-838

Primary sclerosing cholangitis, Bile duct disease, Liver disease

Phase 2

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IMU-856

Psoriasis

Phase 1

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

IMU-935

Psoriasis

Phase 1

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

IMUX

BPIQ_Logo_RGB-01.jpg

Company Profile

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.

Recent Posts

See what the community is saying - click to see full post.

COVID-19 Therapeutic Stocks to Watch (June 2021)

IMUX - Announces Results From Interim Safety Analysis From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19